Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial

JAMA Psychiatry

Volumn 75, Issue 2, 2018, Pages 139-148

  Daly, Ella J ^a   Singh, Jaskaran B ^b   Fedgchin, Maggie ^a   Cooper, Kimberly ^b   Lim, Pilar ^a   Shelton, Richard C ^c   Thase, Michael E ^d   Winokur, Andrew ^e,f   Van Nueten, Luc ^b   Manji, Husseini ^a   Drevets, Wayne C ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e INSTITUTE OF LIVING   (United States)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ESKETAMINE; PLACEBO; KETAMINE;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISSOCIATIVE DISORDER; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV-TR; DYSGEUSIA; ECTOPIC PREGNANCY; ELEVATED BLOOD PRESSURE; FAINTNESS; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT DEPARTMENT; PHASE 2 CLINICAL TRIAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCREENING; SEDATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT DEPRESSION; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MAJOR DEPRESSION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KETAMINE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85041692697     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.3739     Document Type: Article

References (49)

1. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-138.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.
3. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA. 1989;262(7):914-919.
4. Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STAR∗D report. Ann Clin Psychiatry. 2010;22(1): 43-55.
5. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: ameta-analysis. Psychosom Med. 2001;63(4):619-630.
6. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-226.
7. Penninx BW. Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. Neurosci Biobehav Rev. 2017;74(Pt B): 277-286.
8. Rahe C, Khil L, Wellmann J, Baune BT, Arolt V, Berger K. Impact of major depressive disorder, distinct subtypes, and symptom severity on lifestyle in the BiDirect Study. Psychiatry Res. 2016; 245:164-171.
9. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334-341.
10. The American Psychiatric Association. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. http://psychiatryonline.org/doi/book/10.1176/appi.books.9780890426807. Published 2010. Accessed August 23, 2016.
11. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-249.
12. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354.
13. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864.
14. Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169(11):1150-1156.
15. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013; 170(10):1134-1142.
16. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015; 172(10):950-966.
17. Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 2013;19(6):428-436.
18. Domino EF. Taming the ketamine tiger: 1965. Anesthesiology. 2010;113(3):678-684.
19. Singh JB, Fedgchin M, Daly E, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016; 80(6):424-431.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
21. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325.
22. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477-486.
23. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34 (1):73-82.
24. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194.
25. Chi GYH, Li Y, Liu Y, Lewin D, Lim P. On clinical trials with a high placebo rate. Contemp Clin Trials Commun. 2016;2:34-53. doi:10.1016/j.conctc.2015.10.002
26. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
27. Chen YF, Yang Y, Hung HM, Wang SJ. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials. Contemp Clin Trials. 2011;32(4):592-604.
28. Fava M, Mischoulon D, Iosifescu D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012;81(2):87-97.
29. Chen YF, Zhang X, Tamura RN, Chen CM. A sequential enriched design for target patient population in psychiatric clinical trials. Stat Med. 2014;33(17):2953-2967.
30. Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med. 2013;32(16): 2767-2789.
31. Huang X, Tamura RN. Comparison of test statistics for the sequential parallel design. Stat Biopharm Res. 2010;2(1):42-50.
32. Ivanova A, Qaqish B, Schoenfeld DA. Optimality, sample size, and power calculations for the sequential parallel comparison design. Stat Med. 2011;30(23):2793-2803.
33. Papakostas GI, Shelton RC, Zajecka JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267-1274.
34. Tamura RN, Huang X. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials. 2007;4(4): 309-317.
35. Rybin D, Doros G, Pencina MJ, Fava M. Placebo non-response measure in sequential parallel comparison design studies. Stat Med. 2015;34(15): 2281-2293.
36. Tamura RN, Huang X, Boos DD. Estimation of treatment effect for the sequential parallel design. Stat Med. 2011;30(30):3496-3506.
37. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583.
38. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
39. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Åsberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52-58.
40. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222.
41. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-1097.
42. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress. 1998;11(1):125-136.
43. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
44. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics. 2005;61(3): 738-748.
45. Liu Q, Lim P, Singh J, Lewin D, Schwab B, Kent J. Doubly randomized delayed-start design for enrichment studies with responders or nonresponders. J Biopharm Stat. 2012;22(4):737-757.
46. Khan A, Fahl Mar K, Faucett J, Khan Schilling S, Brown WA. Has the rising placebo response impacted antidepressant clinical trial outcome? data from the US Food and Drug Administration 1987-2013. World Psychiatry. 2017;16(2):181-192.
47. White PF, Schüttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57(2):197-203.
48. clinicaltrials.gov. A Double-Blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide Ideation, in Participants Who Are Assessed to Be at Imminent Risk For Suicide. NCT02133001. https://clinicaltrials.gov/ct2/show/NCT02133001. Accessed November 6, 2017.
49. clinicaltrials.gov. A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1). NCT02493868. https://clinicaltrials.gov/ct2/show/NCT02493868. Accessed November 1, 2017.